anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a method for producing powder of Suitetsu (dried Hirudo) with which dried Hirudo is dried and powdered without impairing various physiologically active substances contained in dried Hirudo and to obtain powder of dried Hirudo prepared by the production method and a thrombolysis promotion composition containing the powder of dried Hirudo.  &lt;P&gt;SOLUTION: Powder of dried Hirudo is obtained by washing dried Hirudo, immersing the washed dried Hirudo in ethanol, freeze-drying and grinding dried Hirudo immersed in ethanol. Preferably antioxidation treatment using nitrogen gas is carried out before grinding the freeze-dried dried Hirudo. Preferably the freeze-dried and ground dried Hirudo is thermally sterilized. The thrombolysis promotion composition comprises the powder of dried Hirudo thus obtained as an active ingredient.  &lt;P&gt;COPYRIGHT: (C)2006,JPO&amp;NCIPI
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a sequence related to cancer (especially carcinogenesis and breast cancer).  &lt;P&gt;SOLUTION: Provided is a novel sequence related for use in the diagnosis and treatment of carcinomas (especially breast cancers). In addition, described is the use of novel compositions for use in screening methods. Provided are compositions and methods in cancer associated with altered expression of PRDM11. Provided is a method for screening a medicine candidate. The method includes the processes of: (a) a process for providing a cell which contains a nucleic acid sequence selected from the group consisting of specific sequence and its fragments and expresses a cancer-associated (CA) gene; (b) a process for adding the medicine candidate to the cell, and (c) a process for determining the effect of the medicine candidate in the expression of the CA gene.  &lt;P&gt;COPYRIGHT: (C)2009,JPO&amp;INPIT
PROBLEM TO BE SOLVED: To provide a new Frizzled-4 polypeptide containing an amino acid sequence having high identity to a sequence over the whole length of a specific amino acid sequence and useful for the treatment diagnosis, etc., of neurological disorder, cancer, osteopathy, cardiovascular disease, apoplexy, etc. SOLUTION: The objective polypeptide is a separated new Frizzled-4 polypeptide containing an amino acid sequence having an identity of at least 98% to the amino acid sequence of the formula over the whole length of the formula. It is useful for the treatment diagnosis, etc., of neurological disorder (e.g. schizophrenia, bipolar/monopolar disorder, Alzheimer&#39;s disease and epilepsy), cancer, osteopathy (e.g. osteoporosis-pseudoglioma syndrome), cardiovascular disease, apoplexy, type I Usher&#39;s syndrome development disorder, etc. The polypeptide can be produced by standard cloning and screening technique from a DNA library induced from mRNA in human placenta cell by producing a polynucleotide from the library by expressed sequence tag(EST) analysis and expressing the polynucleotide in a host cell.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a nucleic acid molecule encoding a new polypeptide, to recombine and produce the polypeptide, to provide an isolated nucleic acid containing a nucleotide sequence encoding a PRO polypeptide, to provide the isolated PRO polypeptide, and to provide a vector containing a vector containing a DNA encoding an arbitrary polypeptide.  &lt;P&gt;SOLUTION: The nucleic acid molecule encoding a new polypeptide. A host cell and a vector each containing these nucleic acid sequences. A chimera polypeptide molecule containing a polypeptide fused with a different kind of a polypeptide sequence. An antibody to be bound to the polypeptide. A method for producing the polypeptide.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
A healthcare risk index is generated using a patient or individual&#39;s medical claims. The index may be used to explain and predict variation in pharmacy-related costs and variation in total healthcare costs or utilization. In particular, one example of such a method involves first generating a medical condition score using the individual&#39;s medical information for each medical condition possessed by the individual. From there, each medical condition score is modified according to a regression coefficient, to result in one or more modified medical condition scores. Finally, the risk index may be generated by summing the medical condition scores. This risk index is indicative of at least one of the individual&#39;s medical costs, chronic medical conditions, and variation in medical costs.
The present invention provides an amphiphilic phthalocyanine-based compound and metal chelates and salts thereof, wherein said compound possesses four peripheral ring systems in which one of said ring systems is more hydrophilic and has more hydrophilic group(s) than any one of the three remaining ring systems. Thus the compounds may be of formula (I) (wherein each of X&lt;1&gt;, X&lt;2&gt;, X&lt;3&gt; and X&lt;4&gt; together with the intervening ring carbon atoms independently represents an optionally substituted mono-, bi- or tri-cyclic aromatic or heteroaromatic ring system; with the provisos that (i) X&lt;1&gt; is linked via one or more linker groups, L, to at least one hydrophilic group wherein said hydrophilic group(s) together consists of, or contains, two or more groups which have a pKa &lt; 4.0 when attached at position 5 on isoindole, and that (ii) where substituted, any ring system X&lt;2&gt;, X&lt;3&gt;, or X&lt;4&gt; is less hydrophilic than the ring system X&lt;1&gt;; and each L, which may be the same or different, represents a bond or an organic linker group). The hydrophilic group present in the ring system X&lt;1&gt; is preferably selected from the radicals of sulfonic acids, phosphonic acids, phosphoric acids, carboxylic acids, mono sulfate amides, mono phosphate amides and groups which result in sulfate or phosphate esters on attachment to the ring structure. Such compounds may be used as photosensitizing agents in photodynamic therapy (PDT, eg photochemotherapy), diagnosis, or may be used to introduce a transfer molecule into the cytosol of a cell (photochemical internalisation). Thus such compounds may be used in gene therapy or to treat cancer, rheumatoid arthritis, cardiovascular diseases (eg atherosclerosis) infections (eg viral), skin disorders (eg psoriasis, acne and abrasions) solar keratosis, wound healing, fracture healing, warts, inherited genetic disorders (eg cystic fibrosis), Gorlin&#39;s syndrome or ataxia telangiectasia. Pharmaceutical compositions and kits comprising such compounds are also disclosed.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a first agent for permanent waving, enabling the amount of an used alkali agent to be decreased by heightening the formative ability (waving effect) of the wave and durability (wave retention) of the wave to the hair.  &lt;P&gt;SOLUTION: The first agent for the permanent waving contains porphyrin. The porphyrin is preferably one kind or a combination of two kinds of hematin, sodium iron chlorophyllin and sodium copper chlorophyllin. When the porphyrin is the hematin, the concentration of the hematin is preferably ≥0.001 wt.% and ≤0.015 wt.%. When the porphyrin is the sodium iron chlorophyllin, the concentration of the sodium iron chlorophyllin is ≥0.0001 wt.% and ≤0.005 wt.%.  &lt;P&gt;COPYRIGHT: (C)2007,JPO&amp;INPIT
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a comfortable environment without giving an unpleasant feeling and imposing time and labor in a painting work by succeeding beauty in a conventional manner and obtaining a nail treatment cosmetic for finish corresponding to painting through the use of film shape enamel, a makeup method, and a cosmetic tool therefor.  &lt;P&gt;SOLUTION: The nail treatment cosmetic contains an enamel film 1 including a composition to be used for a nail treatment material, a film fixer 3, and a finishing agent 4. The film fixer 3 is a volatile or adhesive composition mainly containing an alcohol solvent. The finishing agent 4 consists of an oil solution such as silicone, paraffin, and animal/vegetable oil, so as not to deteriolate the enamel film by a low surface tension value, and is a fluid having surface tension not more than 40mN/m. The membrane 1 is softened by the film fixer 3 and coated on a finger part by permitting protrusion. A protrusion part is removed by a deformation peeling action through the use of the finishing agent 4. Under the existence of the oil solution with the low surface tension, only the protruded film to be deformed in a skin part is peeled. A difference in deformation property between the nail and the skin is utilized concerning the sticking part of the membrane 1.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
NEW MATERIAL:A compound shown by the formula I (R&lt;1&gt; is 1-25C alkyl; R&lt;2&gt; is 1-6C alkyl; R&lt;3&gt;-R&lt;5&gt; are 1-6C alkyl, H, or aralkyl; A is 1-6C alkylene). EXAMPLE:A compound shown by the formula VI. USE:An anti-inflammatory agent, analgesic, or germicide. Having low stimulating action on the stomach and low toxicity. PREPARATION:A glycerin dialkyl ether shown by the formula II is reacted with phosphorus oxychloride in the presence of a base to give a compound shown by the formula III. Then, this compound shown by the formula III is reacted with an amine shown by the formula IV to give a compound shown by the formula V. Then, the compound shown by the formula V is subjected to ring opening with an acid, to give a compound shown by the formula Ia wherein R&lt;4&gt; of the formula I is H, and R&lt;2&gt; is H.
PROBLEM TO BE SOLVED: To provide a liposome having small particle diameter. SOLUTION: This liposome is obtained by subjecting water having &lt;=90 Hz half width of 17O-NMR signal, the objective substance and an amphiphilic compound to ultrahigh pressure homogenizer treatment. An average particle diameter of the liposome is smaller than an average particle diameter of liposome produced by using usual water. Preferably, the amphiphilic compound is lecithin. A composition containing a medicinal agent, a cosmetic, a hair growing agent or a hair nourishing agent in the liposome has excellent miscibility with the texture and the medicinal agent, a humectant composition, a hair growing component or a hair nourishing component, etc., is facilitated to attach or penetrate in the texture and a high effect is expected in cooperation with a sustained release property. Especially, in the case of using water having &lt;=60 Hz half width of the signal, the liposome has an ability of dispersing oils and fats more than 1.5 times than usual water, therefore, more amounts of medicinal agent, cosmetic, hair growing agent or hair nourishing agent in the liposome, thus more higher effect can be expected.
In preparing radio-active threads by impregnation with soluble radio-active salts, e.g. radium bromide, followed by treatment with precipitants for the radio-active substance, e.g. ammonium sulphate, the threads are afterwards washed in repeatedly renewed pure water until no radio-active compounds can be detected in the washing water; or the washing may be made more effective by removing radio-active material from the superficial layers of the fibre by treatment with a solvent, e.g. alkali carbonate, for the insoluble material.  This may be followed by washing with dilute acids, e.g. hydrochloric or sulphuric acids or dilute sulphate solutions.  The threads may be finally coated with rubber, resin, &amp;c.
NEW MATERIAL:4&#39;-Carboxybenzoylanthranylic acid of formula I and its salt. USE:An agent for suppressing the side effect of antitumor agents. If effectively suppresses the side effect caused by the administration of antitumor agents, e.g. renal disorder and the increase in urea nitrogen in blood caused by the disorder. PREPARATION:The compound of formula I can be produced by reacting anthranylic acid of formula II with terephthaloyl chloride of formula III in a solvent such as benzene, dioxane, etc., at 0-40 deg.C, preferably at room temperature for 2-10hr. The amount of the compound of formula III is 1-2mol per 1mol of the compound of formula II and the reaction is carried out keeping the reaction solution in alkaline state, preferably at &gt;=11pH.
Disclosed are an mRNA for expressing the varicella-zoster virus antigen protein and use thereof. The mRNA comprises a 5&#39; untranslated region, an open reading frame, a 3&#39; untranslated region, and a polyadenylic acid tail in sequence in the direction from 5&#39; to 3&#39;, wherein the nucleotide sequence of the 5&#39; untranslated region is represented by any of SEQ ID NOs. 23, 24, 25, 26 and 27; the nucleotide sequence of the 3&#39; untranslated region is represented by any of SEQ ID NOs. 28 and 29; and the open reading frame encodes the varicella-zoster virus antigen protein. The average protein expression level of the mRNA with optimized sequences obtained by the present invention is relatively high. Pharmacodynamic verification experiments have shown that the mRNA has an immunostimulation effect; when the mRNA is wrapped with LNP to form mRNA-vector particles, the immune effect can be equivalent to that of a recombinant protein antigen. The mRNA can be used for preparing an mRNA vaccine.
A system and a method for monitoring individual metabolic response and for generating nutritional feedback involve monitoring of glycemic response in a qualified subject. A plurality of measurements of the glucose level in the qualified subject are consecutively performed by a measuring device (100). In the measuring device (100) first data corresponding to the measured glucose level is generated. Subsequently, the data is transmitted to an analysis device (200), where second data is generated from a time-series of glucose level measurements represented by the first data. In a next step, the second data is compared with a predetermined individual glycemic response budget for the qualified subject, the individual glycemic response budget representing a total amount of individual glycemic response allowable for a certain time period. Finally, feedback corresponding to the result of the comparison is provided by an output device (200). Continuously monitoring the glucose level of qualified subjects can provide highly personalized information about the effects of diet, physical activity, and nutrition by revealing an individual&#39;s glycemic response to ingested food and beverages. The inventive method and system are therefore valuable tools for supporting weight management, nutritional counseling, and preventive medicine.
&lt;P&gt;PROBLEM TO BE SOLVED: To find a new DNA synthetase inhibitor substance and to provide its utilization method.  &lt;P&gt;SOLUTION: The novel DNA synthetase inhibitor substance is isolated from tobacco culture cells, then purified, and subjected to structural analysis; thus, it is made clear that the new synthetase inhibitor substance is a new dipeptide composed of homoserine and ethanolamine combined with each other by a peptide bond. The new dipeptide has an inhibition activity for selectively inhibiting a DNA synthetase ε, and its homologous compounds are also recognized as having a DNA synthetase inhibition activity. Therefore, the new dipeptide and its homologous compounds are useful as DNA synthetase inhibitors, biochemical reagents, and medicines, e.g. an anticancer agent.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
Bioscaffoldings formed of hydrogels that are crosslinked in situ in an infarcted region of the heart (myocardium) by a Michael&#39;s addition reaction or by a disulfide bond formed by an oxidative process are described. Each of the bioscaffoldings described includes hyaluronan as one of the hydrogel components and the other component is selected from collagen, collagen-laminin, poly-l-lysine, and fibrin. The bioscaffolding may further include an alginate component. The bioscaffoldings may have biofunctional groups such as angiogenic factors and stem cell homing factors bound to the collagen, collagen-laminin, poly-l-lysine, or fibrinogen hydrogel component. In particular, the biofunctional groups may be PR11, PR39, VEGF, bFGF, a polyarginine/DNA plasmid complex, or a DNA/polyethyleneimine (PEI) complex. Additionally, the hydrogel components may be injected into the infarct region along with stem cells and microspheres containing stem cell homing factors. The bioscaffolding may be formed on a stent or a cardiac medical device.
PURPOSE:A radiation sensitizer for increasing extremely susceptibility of inveterate low-oxygen cell existing in a malignant tumor to radiation, containing a specific dinitrobenzoic acid derivative as an active ingredient. CONSTITUTION:A radiation sensitizer containing a dinitrobenzoic acid derivative shown by the formula [R is OM1/a, OR1, N(R2)R3; M is metal of group I a or IIa; a=1 or 2; R1-3 are, H, alkyl, etc.; R2 and R3 are bonded each other to show alkylene, oxadialkylene, etc.] as an active ingredient. The compound shown by the formula is found to increase extremely susceptibility of low-oxygen cell to radiation and to enlarge radiation remedying effect on a malignant tumor. A dose is sufficiently &lt;=1/50 that of misonidazole well-known as a sensitizer, and the compound has hardly toxicity with this amount of it.
FIELD: organic chemistry, antibiotics, pharmacy. SUBSTANCE: invention relates to new antibiotics of carbapenem group and their nontoxic pharmaceutically acceptable salts exhibiting antibacterial activity. They can be used both separately and in combination with other antibiotics for treatment of human and animals with bacterial infections. Compounds of the formula (I)   where moiety -S-  means 5-membered heterocyclic substituted ring where: (A) Z means oxygen, sulfur atom; (B) R 0  means -CH(OR 4 )CH 3  where R 4  means hydrogen atom; (C) R 1  means (C 1 -C 3 )-alkyl. Substituents of a group -S-  are taken from (CH 2 ) n R 2  where: (D) n is a whole number from 0 to 4; (E) R 2  means: (1) methyl-group, bromine, chlorine, iodine atom, -OSO 2 CH 3 , azido-group; (II) a group of the formula -S(O) n ″R a  where n&#39;&#39; is a whole number from 0 to 2; R a  means a group bound by carbon atom and taken from substituted or nonsubstituted (C 1 -C 6 )-alkyl, substituted or nonsubstituted phenyl, substituted or nonsubstituted phenyl-(C 1 -C 6 )-alkyl being chlorine, bromine atoms and hydroxy-group can be substituents; (III) R 2  is taken from hydroxy-group, OR a , OC(O)NR a R a  where R a  means independently values indicated above or   where R 13  means   and B -  is a physiologically acceptable anion; (IV) or R 2  means a residue bound by nitrogen atom and means: formula (a)   where R p  means oxygen atom; R L  and R J  mean independently hydrogen atom, alkyl, substituted or nonsubstituted amine, heterocycle where heterocycle means 5- or 6-membered ring containing two atoms N or O; or R L  and R J  with the bound nitrogen atom form nonsubstituted monocyclic ring containing two heteroatoms taken independently form O or N being substituents are hydroxyl, oxo-group; (b) acyclic quaternary ammonium group of the formula:   where R 7 , R 8 , R 9  mean alkyl; B -  is a physiologically acceptable anion; (V) or R 2  means a group bound by carbon atom and has a formula:   where R 2  and R 3  are indicated above, and pharmaceutical acceptable salts of the compound described. Invention relates to also a method of synthesis of antibiotics of carbapenem group and some intermediate compounds. Invention proposes methods of treatment of human and animals with infectious diseases that involve administration of the above indicated compounds to human or animals and pharmaceutical preparations containing these compounds. EFFECT: improved method of synthesis and treatment. 6 cl, 14 dwg, 409 ex
The invention discloses a double-functional nano-composite spheres based on metal ion-inducing polypeptide self-assembly and a preparation method thereof. In the invention, by means of a one-step reaction synthesis method, with [alpha]-lactalbumin hydrolyzed polypeptide as a carrier, the nano spheres are self-assembled under induction by Ca&lt;2+&gt; and Gd&lt;3+&gt; together, wherein the nano spheres, during self-assembly, are wrapped by a photosensitive agent, rose Bengal. The particle size of the nano-composite spheres can be adjusted and controlled in the range of 100-500 nm. The Gd&lt;3+&gt; which participates in the inductive sphere forming is used as a contrast medium unit of magnetic resonance imaging and the T1-weighted nuclear magnetic resonance signal response can be effectively increased so that the magnetic resonance imaging diagnosis to a tumor site can be performed. The rose Bengal wrapping the nano-composite spheres can release singlet oxygen to kill tumor cells under excitation illumination at 550 nm, thereby achieving the effect of photodynamic treatment. The nano-composite spheres are toxic-free without illumination. Meanwhile, the treatment process allows tracing through the magnetic resonance imaging. In addition, the nano-composite spheres are low in preparation cost, are simple in processes, and have a potential wide application prospect in the bio-medicinal field.
FIELD: medicine. ^ SUBSTANCE: for correction of hyperhomocysteine-induced endothelial dysfunction in white rat males of Wistar line modeled is endothelial dysfunction by intragastric introduction of methionine in dose 3 g/kg daily during 7 days. Degree of dysfunction development is estimated by ratio of indices of endothelium-independent and endothelium-dependent vasodilatation, as well as by increase of homocysteine concentration. Correction of endothelial dysfunction is carried out by intragastric introduction of medication &#34;Phosphogliv&#34; capsules in dose 2.2 g/kg once per day an hour after methionine introduction. ^ EFFECT: method insures study of correction of hyperhomocysteine-induced endothelial dysfunction by means of phosphogliv with creation of definite model of said pathology. ^ 2 tbl
&lt;P&gt;PROBLEM TO BE SOLVED: To easily and surely create patient&#39;s data for each purpose of research and clinical trial as statistical information while securing the concealment and to collect and archive the data, in a system for providing and acquiring medical information by a two-way communication network.  &lt;P&gt;SOLUTION: The statistical information is processed by providing and acquiring centralized processing medical information by the two-way communication network. Communication equipment 4 in a medical institution respectively disposed at a plurality of hospitals conducts access for processing the statistical information to fetch a transferred patterned format for inputting data on a patient. Only the patient data in the patterned format is fetched out for transfer. Communication equipment 3 in a medical information centralized processing center transfers the patterned format for creating the statistical information is correspondence with the access from the communication equipment 4 in the medical institution. The patient&#39;s data transferred from the communicating equipment 4 in the medical institution is stored and archived.  &lt;P&gt;COPYRIGHT: (C)2003,JPO
PROBLEM TO BE SOLVED: To obtain a cerebral function improving agent containing N- acetylneuraminic acid bonded oligosaccharides promoting the metabolism of cerebral phospholipid and gangliosides. SOLUTION: This agent contains the N-acetylneuraminic acid bonded oligosaccharides expressed by the formula (Gal)n-Neu5Ac (Gal is galactose residue; Neu5Ac is N-acetylneuraminic acid residue; (n) is 1 or 2), as the active ingredient. Other suitable conventional ingredients are blended and can be prepared in conventional method. This compound can be used in food and drink such as yogurt, cheese, bread, drinkable beverage, etc. The adult&#39;s dosage of the N-acetylneuraminic acid bonded oligosaccharides is at least 10mg/kg per day, preferably 30 to 100mg/kg per day. The N-acetylneuraminic acid bonded oligosaccharides is an oligosaccharides in which galactose is bonded with N- acetylneuraminic acid, obtained by glycosyltransfer reaction of β-galactosidase using lactose and N-acetylneuraminic acid or its salt as the raw material.